Latest Product Development News

VEEM Limited has finished its factory extension and installed new machinery, setting the stage for a stronger second half of FY26 and anticipated growth in FY27 driven by defence contracts and marine propulsion innovations.

ArborGen Holdings announces CEO Justin Birch's resignation after three years, appointing Patrick Cumbie as interim CEO while searching for a permanent replacement.

Treasury Wine Estates (ASX:TWE) unveils its Ascent transformation, targeting $100 million annual savings, portfolio focus on Power Brands, and a leaner supply chain to lift margins and reduce leverage by FY28.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Swift TV has completed a multi-year Google certification process for its enterprise connected TV platform, validating its technology and supporting ongoing deployments across mining, aged care, and hospitality sectors.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

QuickFee Limited has reported a robust 77% increase in Australian originations for Q4 FY26 to-date, driven by strong Fee Funding and Disbursement Funding growth. The company boosted its Australian credit facility by A$15 million, signalling confidence in its low-risk lending model, while US operations focus on reseller channel expansion amid a product embedding delay.

ReadyTech Holdings has dismissed an unsolicited acquisition proposal valuing the company at $2.00 per share, calling it undervalued and unworkable. The offer includes a parallel off-market bid at $1.75 per share with a 50.1% minimum acceptance condition.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Advanced Energy Minerals (ASX:AEM) is ramping up its Cap-Chat high purity alumina production, targeting 3,000 tpa by mid-2026 and planning to double capacity to 6,000 tpa by 2029 amid a forecast supply deficit and surging demand.

Argosy Minerals has achieved 99% lithium chloride purity and 94.4% lithium recovery in pilot plant test works for its 12,000tpa Rincon Lithium Project, underpinning its move toward industrial-scale production and advancing its Definitive Feasibility Study.